Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter

BIODESIX INC

2023-Q1 EPS reported -$0.50 revenue$6,548,000

Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.
Net loss $15.6M (increase 124% YoY); operating expenses $17.8M, up 10%.
Raised $27.4M post-Q1: $11.7M private placement, $2.7M ATM, $13M net from $25M debt facility.
Restructured Indi milestone payments, reducing 2022 pay by $7.5M and 2023 by $7.2M.
Reaffirmed FY2022 total revenue outlook of $37.5M-$39.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.